3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
114
Carcinoma, Non-Small-Cell Lung
34
Neoplasms
26
Neoplasm Metastasis
19
Prostatic Neoplasms
18
Uveal Melanoma
16
Carcinoma, Renal Cell
16
Lung Neoplasms
14
Pancreatic Neoplasms
13
Diabetes Mellitus, Insulin-Dependent, 12
12
Small Cell Lung Carcinoma
11
Colorectal Neoplasms
10
Carcinoma, Hepatocellular
9
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
8
Breast Neoplasms
8
Sarcoma
7
Carcinoma, Transitional Cell
7
Brain Neoplasms
7
Stomach Neoplasms
6
Mesothelioma
6
Kidney Neoplasms
6
Head and Neck Neoplasms
6
Advanced Cancer
6
Urinary Bladder Neoplasms
5
Recurrence
5
Ovarian Neoplasms
5
Lymphoma, Non-Hodgkin
5
Lymphoma
5
Leukemia, Myeloid, Acute
5
Interventions
Gemcitabine
7
130-nm albumin-bound paclitaxel
5
Fluorouracil
3
Albumin-Bound Paclitaxel
3
dehydroftorafur
2
Taxes
2
Oxaliplatin
2
tocilizumab
1
selicrelumab
1
niraparib
1
cobimetinib
1
atezolizumab
1
Tiragolumab
1
Resistance Training
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Image-Guided
1
Radiotherapy, Conformal
1
Pancreatectomy
1
PEGPH20
1
Nivolumab
1
Leucovorin
1
Irinotecan
1
Ipilimumab
1
Interleukin 1 Receptor Antagonist Protein
1
Erlotinib Hydrochloride
1
Electronic Health Records
1
Cisplatin
1
Bevacizumab
1
4-fluorobenzoyl-TN-14003
1
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Pancreatic Adenocarcinoma
×
Ipilimumab
×
Clear all
NCT03404960
2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2
Completed
104 enrolled
11 charts